Dan Switzer is the Head of the US Oncology Business Division for Daiichi Sankyo. In this role he is accountable for all US business, and he is responsible for the commercialization and performance of all in-line and near-term oncology assets. He oversees the Sales, Marketing, Market Access, Medical Affairs and Business Operations functions for the US. He also serves on the leadership team for the Global Oncology Business Unit. In addition to his responsibilities leading the OBD, Dan is a member of the Daiichi Sankyo, Inc. Board of Directors. Dan has been with Daiichi Sankyo since 2005, holding leadership roles in brand management, market access, and business analytics. Throughout his time at DSI he has launched multiple pharmaceuticals and biologics and overseen multi-billion-dollar franchises. Since 2020, Dan has led the transformation of the Daiichi Sankyo US commercial and medical organization into an oncology company.